CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $10.09B, above the global median of $1.15B
- FinancialsAltman Z-Score 6.02: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.86%Above 5Y avg (0.53%)
Annual Rate
INR 18.00Paid annual
Payout Ratio
9.9%Sustainable
Last Ex-Dividend
Jul 17, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
961.59BINR10.09B · vs all stocks (USD)
Trailing P/E
17.52xRevenue (TTM)
299.67BINR3.15B · vs all stocks (USD)
Profit Margin
18.45%Beta
0.1630xvs all stocks
52-Week Change
5.62%vs all stocks
Market Capitalization
961.59BINR10.09B · vs all stocks (USD)
Enterprise Value
959.14BINR10.07B · vs all stocks (USD)
Trailing P/E
17.52xForward P/E
20.71xPEG Ratio
0.2115xPrice to Sales (TTM)
3.23xPrice to Book (MRQ)
4.31xEnterprise to Revenue
3.20xEnterprise to EBITDA
11.10xGross Margin
74.57%Profit Margin
18.45%Operating Margin
25.35%Return on Assets (TTM)
13.90%Return on Equity (TTM)
23.69%Revenue (TTM)
299.67BINR3.15B · vs all stocks (USD)
Revenue per Share (TTM)
655.82INRUpdated Sep 23, 2026Quarterly Revenue Growth
32.00%Gross Profit (TTM)
216.84BINR2.28B · vs all stocks (USD)
EBITDA (TTM)
93.89BINR985.47M · vs all stocks (USD)
Net Income (TTM)
55.29BINR580.30M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
16.10%Operating Cash Flow (TTM)
73.34BINR769.83M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
53.33BINR559.73M · vs all stocks (USD)
Trailing Annual Dividend Rate
18.00INRUpdated Sep 23, 2026Trailing Annual Dividend Yield
0.86%vs all stocks
5-Year Average Dividend Yield
0.53%vs all stocks
Payout Ratio
9.94%Minority Interest (Equity)
651.00MINRFY2026 · Mar 31, 2026Revenue
274.88BINRFY2026 · Mar 31, 2026Cost of Goods Sold
81.11BINRFY2026 · Mar 31, 2026Gross Profit
193.77BINRFY2026 · Mar 31, 2026Operating Income
68.18BINR715.66M · vs all stocks (USD)
Pre-tax Income
68.73BINRFY2026 · Mar 31, 2026Income Tax Expense
15.17BINRFY2026 · Mar 31, 2026Net Income
53.55BINRFY2026 · Mar 31, 2026EBIT
72.85BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
90.64BINRFY2026 · Mar 31, 2026Selling, General & Administrative
35.93BINRFY2026 · Mar 31, 2026Other Operating Expenses
30.58BINRFY2026 · Mar 31, 2026Non-operating Interest Income
2.17BINRFY2026 · Mar 31, 2026Non-operating Interest Expense
4.13BINRFY2026 · Mar 31, 2026EPS (Basic)
116.75INRFY2026 · Mar 31, 2026EPS (Diluted)
116.44INRFY2026 · Mar 31, 2026Basic Shares Outstanding
456.78MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
456.78MSharesFY2026 · Mar 31, 2026Minority Interests (P&L)
-226.30MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
65.71BINRFY2026 · Mar 31, 2026Free Cash Flow
47.63BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
41.68BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
68.73BINRFY2026 · Mar 31, 2026Stock-based Compensation
389.50MINRFY2026 · Mar 31, 2026Other Non-cash Items
2.16BINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-7.39BINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
1.82BINRFY2026 · Mar 31, 2026Capital Expenditures
-18.07BINRFY2026 · Mar 31, 2026Net Acquisitions
-1.05BINRFY2026 · Mar 31, 2026Purchase of Investments
-188.47BINRFY2026 · Mar 31, 2026Sale of Investments
164.66BINRFY2026 · Mar 31, 2026Other Investing Activity
2.11BINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-40.81BINRFY2026 · Mar 31, 2026Long-term Debt Issuance
0.00INRFY2026 · Mar 31, 2026Long-term Debt Payments
0.00INRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
2.79BINRFY2026 · Mar 31, 2026Common Stock Repurchase
-670.70MINRFY2026 · Mar 31, 2026Common Dividends Paid
-5.48BINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-3.20BINRFY2026 · Mar 31, 2026Shares Outstanding
457.29MSharesUpdated Sep 23, 2026Float Shares
242.08MSharesUpdated Sep 23, 2026% Held by Insiders
47.02%vs all stocks
% Held by Institutions
36.23%vs all stocks
Total Cash (MRQ)
78.95BINR828.62M · vs all stocks (USD)
Total Cash per Share (MRQ)
172.68INRUpdated Sep 23, 2026Total Debt (MRQ)
66.16BINR694.43M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2939xCurrent Ratio (MRQ)
1.90xBook Value per Share (MRQ)
491.02INRUpdated Sep 23, 2026Total Assets
383.65BINR4.03B · vs all stocks (USD)
Total Current Assets
240.27BINRFY2026 · Mar 31, 2026Total Liabilities
158.51BINRFY2026 · Mar 31, 2026Total Non-current Assets
143.37BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
32.00BINRFY2026 · Mar 31, 2026Total Current Liabilities
126.51BINRFY2026 · Mar 31, 2026Cash
37.84BINRFY2026 · Mar 31, 2026Cash Equivalents
5.22BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
43.06BINRFY2026 · Mar 31, 2026Other Short-term Investments
36.42BINRFY2026 · Mar 31, 2026Accounts Receivable
66.04BINRFY2026 · Mar 31, 2026Inventory
60.83BINRFY2026 · Mar 31, 2026Accounts Payable
41.73BINRFY2026 · Mar 31, 2026Short-term Debt
44.78BINRFY2026 · Mar 31, 2026Other Current Liabilities
16.49BINRFY2026 · Mar 31, 2026Long-term Debt
21.38BINRFY2026 · Mar 31, 2026Other Non-current Liabilities
2.58BINRFY2026 · Mar 31, 2026Common Stock (Book)
914.40MINRFY2026 · Mar 31, 2026Retained Earnings
187.97BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
225.13BINR2.36B · vs all stocks (USD)
52-Week Low
1.90KINRUpdated Sep 23, 202652-Week High
2.53KINRUpdated Sep 23, 202652-Week Change
5.62%vs all stocks
Beta
0.1630xvs all stocks
50-Day MA
2.27KINRUpdated Sep 23, 2026200-Day MA
2.27KINRUpdated Sep 23, 2026Avg 10-Day Volume
571.83KSharesUpdated Sep 23, 2026Avg 30-Day Volume
690.63KSharesUpdated Sep 23, 2026Diluted EPS (TTM)
120.81INRUpdated Sep 23, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Is this company growing?
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
How is this stock valued?
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.02: safe zoneNotable
Altman Z-Score: 6.02
High structural barrier to entryNotable
Barrier to Entry: 0.54
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $10.09B, above the global median of $1.15BNotable
Market cap (USD): 10,092,842,090.349Global Median: 1,150,342,212.262
Revenue is $3.15B, above the global median of $559.35MNotable
Revenue (USD): 3,145,292,077.597Global Median: 559,350,010.583
Levered free cash flow is $559.73M, above the global median of $18.98MNotable
Levered free cash flow (USD): 559,734,886.4Global Median: 18,979,762.15
Companies that share the same coordination system — how they create, deliver, or capture value.
Haisco Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Globus Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Bio-Rad Laboratories Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Axsome Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Apogee Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Krystal Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Kelun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nuvalent, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bruker Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Dr. Reddy's Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Hermès International Société en commandite par actions
3 interpretationsPrice Below Mean With Profitability And Book ValueRevenue Growth With Elevated MarginMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Hangzhou XZB Tech Co., Ltd.
3 interpretationsPrice Below Mean With Profitability And Book ValueRevenue Growth With Elevated MarginMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Classys Inc.
3 interpretationsPrice Below Mean With Profitability And Book ValueRevenue Growth With Elevated MarginMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities